Halozyme Announces Expansion of Collaboration and License Agreement with argenx for ENHANZE® Technology https://t.co/PNUAEqEPft
— Halozyme Therapeutics (@halozymeinc) October 6, 2020
In case you missed it: Our vice president of global partnering, Renee Tannenbaum, is a finalist for the 2020 National Xconomy Awards in the Secret Weapon category. Winners will be announced tomorrow. Best of luck, Renee! https://t.co/QIrPxrajrz pic.twitter.com/EQoTNJuNTe
— Halozyme Therapeutics (@halozymeinc) September 23, 2020
Listen to our vice president of Global Partnering, Renee Tannenbaum, speak with @dslevine on The Bio Report podcast this week regarding our strategic collaborations with pharmaceutical companies. https://t.co/WaZ8gbOAI7
— Halozyme Therapeutics (@halozymeinc) September 17, 2020
In case you missed it: Last month,@FierceBiotech’s @amirahalidrus wrote a feature on our journey to profitability. Read full article here: https://t.co/fRLCXQKaAD
— Halozyme Therapeutics (@halozymeinc) September 3, 2020
Halozyme Reports Significant Recent Achievements and Second Quarter 2020 Results https://t.co/6MIqPLuXCq pic.twitter.com/Nox7ZmTGnu
— Halozyme Therapeutics (@halozymeinc) August 10, 2020
We hope you all are continuing to stay safe and well during this time. Visit our website to read more information on our #COVID19 response https://t.co/iE8OUBXKYX
— Halozyme Therapeutics (@halozymeinc) July 10, 2020
Last week, we announced that @Roche received #FDA approval of a subcutaneous formulation using Halozyme’s ENHANZE® technology.
Read more about the news here: #ICYMI #DrugDelivery https://t.co/T0U57LqpDW
— Halozyme Therapeutics (@halozymeinc) July 7, 2020
Today our partner @Roche received FDA approval of a subcutaneous formulation using Halozyme’s ENHANZE® drug delivery technology. Read more about the news here: https://t.co/T0U57LqpDW pic.twitter.com/ItZOcMO5wC
— Halozyme Therapeutics (@halozymeinc) June 29, 2020
HALOZYME ANNOUNCES ROCHE RECEIVES FDA APPROVAL FOR PHESGOTM (FIXED-DOSE COMBINATION OF PERJETA® AND HERCEPTIN® FOR SUBCUTANEOUS INJECTION) UTILIZING HALOZYME’S ENHANZE® TECHNOLOGY FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE B https://t.co/c32rH7XIBg pic.twitter.com/NAAY1iw7z3
— Halozyme Therapeutics (@halozymeinc) June 29, 2020
HALOZYME TO RECEIVE $10 MILLION MILESTONE PAYMENT FROM JANSSEN https://t.co/HCzM5rDduc pic.twitter.com/PbBShSNlng
— Halozyme Therapeutics (@halozymeinc) June 22, 2020
At Halozyme, we are working hard to improve patient outcomes with our patient-centered approach to subcutaneous drug delivery through collaborative partnerships.
Learn more about our partnerships here: https://t.co/ebnKqq3jSy
— Halozyme Therapeutics (@halozymeinc) June 18, 2020
Halozyme Announces Findings from Janssen's Phase 3 ANDROMEDA Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE® in Light-chain Amyloidosis Presented at European Hematology Association 25th Annual Congress https://t.co/5aNic1ivPE pic.twitter.com/LzNZb04Pht
— Halozyme Therapeutics (@halozymeinc) June 13, 2020
Yesterday's approval highlights Janssen’s commitment to gaining a better understanding of the evolving needs of people living with multiple myeloma, and to the development of new innovations, combinations, and formulations to best meet those needs. https://t.co/K55GuQfgry
— Halozyme Therapeutics (@halozymeinc) June 5, 2020
HALOZYME ANNOUNCES JANSSEN RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR SUBCUTANEOUS DARZALEX® UTILIZING HALOZYME’S ENHANZE® TECHNOLOGY FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA https://t.co/0lQUrOS6v2
— Halozyme Therapeutics (@halozymeinc) June 4, 2020
Learn more about how we use our proprietary rHuPH20 enzyme to break down hyaluronan (HA) in the #subcutaneous space: https://t.co/LrLctMZ2PK #DrugDelivery #SubQ
— Halozyme Therapeutics (@halozymeinc) May 28, 2020
HYLENEX® recombinant (hyaluronidase human injection) and ENHANZE® drug delivery technology are based on our proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20). Learn more about our #enzyme here: https://t.co/NEns1ckBsk #DrugDelivery
— Halozyme Therapeutics (@halozymeinc) May 21, 2020
Halozyme Reports First Quarter 2020 Results https://t.co/UXfhqVRdix pic.twitter.com/T7GdJhi1Mq
— Halozyme Therapeutics (@halozymeinc) May 11, 2020
HALOZYME TO PRESENT AT THE BANK OF AMERICA SECURITIES 2020 HEALTHCARE CONFERENCE https://t.co/xqQkbWlG0i pic.twitter.com/QlbHZugUlI
— Halozyme Therapeutics (@halozymeinc) May 7, 2020
HALOZYME ANNOUNCES JANSSEN SUBMITS NEW DRUG APPLICATION IN JAPAN FOR DARATUMUMAB SUBCUTANEOUS FORMULATION UTILIZING HALOZYME’S ENHANZE® TECHNOLOGY FOR PATIENTS WITH MULTIPLE MYELOMA https://t.co/Bbl29oDQI3 pic.twitter.com/2lEvbOWHy5
— Halozyme Therapeutics (@halozymeinc) April 27, 2020
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2019 RESULTS https://t.co/f1qI7Vgeg9
— Halozyme Therapeutics (@halozymeinc) February 24, 2020
HALOZYME ANNOUNCES CFO TRANSITION https://t.co/SroTVK9rXS
— Halozyme Therapeutics (@halozymeinc) February 24, 2020
HALOZYME REPORTS THIRD QUARTER 2019 RESULTS https://t.co/pW10UU7Ur8
— Halozyme Therapeutics (@halozymeinc) November 12, 2019
Halozyme Announces Actions to Focus Strategy on ENHANZE® Drug Delivery Technology https://t.co/G1X2BOg8lO
— Halozyme Therapeutics (@halozymeinc) November 4, 2019
Halozyme Announces HALO-301 Phase 3 Study Fails to Meet Primary Endpoint https://t.co/4oEmaD17y3
— Halozyme Therapeutics (@halozymeinc) November 4, 2019
Halozyme continued its partnership with @PanCAN at this year’s PurpleStride event – see the video for some of the day’s highlights. pic.twitter.com/ltNXg58XKx
— Halozyme Therapeutics (@halozymeinc) October 28, 2019
Positive Results Announced from Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination of Perjeta® and Herceptin® using Halozyme’s ENHANZE® Drug Delivery Technology https://t.co/pJf45PCi4C pic.twitter.com/o1QqEcNfVF
— Halozyme Therapeutics (@halozymeinc) September 13, 2019
HALOZYME REPORTS SECOND QUARTER 2019 RESULTS https://t.co/K6XK11liZT pic.twitter.com/EIh7wID9Td
— Halozyme Therapeutics (@halozymeinc) August 6, 2019
HALOZYME ANNOUNCES JANSSEN SUBMITS EXTENSION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR SUBCUTANEOUS FORMULATION OF DARZALEX® UTILIZING ENHANZE® TECHNOLOGY https://t.co/Soa9UcPDKM pic.twitter.com/7A7htcOV18
— Halozyme Therapeutics (@halozymeinc) July 19, 2019
Halozyme announces first clinical dosing in argenx’s phase 1 trial of efgartigimod (ARGX-113) with ENHANZE® Drug Delivery Technology https://t.co/g2bTh7O59V pic.twitter.com/JuomNE9TkF
— Halozyme Therapeutics (@halozymeinc) July 17, 2019
HALOZYME ANNOUNCES CRADA WITH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES FOR USE OF ENHANZE® DRUG DELIVERY TECHNOLOGY https://t.co/DMndueRMEl pic.twitter.com/6hCztbCjIe
— Halozyme Therapeutics (@halozymeinc) June 25, 2019
Congratulations to @CanaleComm CEO Carin Canale-Theakston for being honored as a 2019 San Diego Entrepreneur of the Year! #EOYSDhttps://t.co/4xymLeusZR
— Halozyme Therapeutics (@halozymeinc) June 7, 2019
HALOZYME ANNOUNCES ARGENX HAS SELECTED SECOND TARGET UNDER ENHANZE® TECHNOLOGY COLLABORATION AND LICENSE AGREEMENT https://t.co/hJElnu2cgC pic.twitter.com/7Bxv2ZeSo0
— Halozyme Therapeutics (@halozymeinc) May 22, 2019
Halozyme Reports First Quarter 2019 Results https://t.co/w1Rp3K0m60 pic.twitter.com/uhLaRTDyDi
— Halozyme Therapeutics (@halozymeinc) May 7, 2019
HALOZYME NAMES DR. ALISON A. ARMOUR AS SENIOR VICE PRESIDENT OF RESEARCH AND DEVELOPMENT https://t.co/rpRnJxemKF pic.twitter.com/yq0LnnrSUp
— Halozyme Therapeutics (@halozymeinc) May 6, 2019
Halozyme’s CEO, Dr. Helen Torley, writes for @endpts on the importance of diverse and inclusive teams and workplaces. Find out more in this article: https://t.co/fchEYJnHHf
— Halozyme Therapeutics (@halozymeinc) May 2, 2019
HALOZYME REPORTS FOURTH QUARTER AND FULL-YEAR 2018 RESULTS https://t.co/VhTkSGn583
— Halozyme Therapeutics (@halozymeinc) February 21, 2019
.@jeopardy host Alex Trebek joins the global movement to raise awareness of the risks and symptoms of #pancreaticcancer for #WPCD. Thank you for your support, Alex! We’re sending you our thoughts as you fight this disease. #DemandBetter pic.twitter.com/3dTlQ0E3IE
— #WPCD (@worldpancreatic) October 30, 2019
$HALO's price moved below its 50-day Moving Average on September 3, 2020. View odds for this and other indicators: https://t.co/YlyYwlUHYl #HalozymeTherapeutics #stockmarket #stock #technicalanalysis #money #trading #investing #daytrading #news #today pic.twitter.com/aWLZbjjGwf
— Tickeron (@Tickeron) October 8, 2020
Stocks with greater movement, last 15 minutes$CRI +/- 0.95% Carter's Inc.$AGO +/- 0.69% Assured Guaranty Ltd.$OCUL +/- 0.67% Ocular Therapeutix Inc.$CMCSA +/- 0.52% Comcast Corporation Class A Co..$HALO +/- 0.51% Halozyme Therapeutics Inc.https://t.co/Pgwd7CHruV
— tradingBotNyse (@tradingbotnyse) October 7, 2020
Brokerages Anticipate Halozyme Therapeutics, Inc. $HALO Will Announce Quarterly Sales of $60.02 Million https://t.co/PurQyTnSwM
— Week Herald (@WeekHerald) October 6, 2020
$HALO – Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE® Technology https://t.co/vGDpkJTYr5
— Stocks News&Markets (@VisualStockRSRC) October 6, 2020
Halozyme Therapeutics, Inc. $HALO Expected to Post Earnings of $0.20 Per Share https://t.co/bJERxTIXA9
— Dispatch Tribunal (@dispatchtribune) October 4, 2020
$0.20 Earnings Per Share Expected for Halozyme Therapeutics, Inc. $HALO This Quarter https://t.co/n4LUXHPED2
— TheOlympiaReport (@OlympiaReport) October 4, 2020
Instinct is telling me $HALO is going down to $23.25.
https://t.co/LjL9I5Bf5v— Blue Healthcare Now (@BlueBioNow) October 3, 2020
Zacks: Analysts Expect Halozyme Therapeutics, Inc. $HALO Will Post Quarterly Sales of $60.02 Million https://t.co/1xWUDhe1ig
— The Markets Daily (@TheMarketsDaily) October 2, 2020
Halozyme expands license agreement with argenx for Enhanze Technology https://t.co/RFWQS7KVnX @businessideas42
— Avinash (@GVRLMAVINASH) October 6, 2020
Thx for nomination! For Day 19, my pick is a fundamental advance in understanding stromal heterogeneity in #PancreaticCancer #pancsm – perhaps explains why indiscriminate targeting of stroma via PEGPH20 (HALO-301) & hedgehog inh failed https://t.co/0yZXQBZ0Qy
— Jash Datta (@DrJashDatta) October 6, 2020
Johnson & Johnson scaled back its Darzalex royalty payments to Genmab in the second quarter, just as its new subcutaneous formulation was hitting the market. Genmab owed a portion of those royalties to drug delivery specialist Halozyme for its subQ tech…https://t.co/lX9zoXU1ai
— Amaro Law Firm (@AmaroLawFirm) October 3, 2020
Halozyme Therapeutics Enters Lucrative Agreement With Pfizer | Drug Development & Delivery
Halozyme Therapeutics Inc (HALO) Q2 2020 Earnings Call Transcript (08/11/2020) | The Motley Fool
Halozyme Therapeutics Inc. | MarketWatch
Halozyme Therapeutics Inc (HALO:NASDAQ) | CNBC
Halozyme Therapeutics Inc. | WSJ Markets
Halozyme Therapeutics Inc. (HALO) | yahoo! finance
Halozyme Therapeutics Inc | Bloomberg
HALOZYME THERAPEUTICS INC. | MARKETS INSIDER
HALO | finviz